IMS Institute recently issued a white paper evaluating the future and potential of biosimilars through 2020.
As biologic medicines play a more significant role in patient care across a growing number of disease areas, the emergence of biosimilar medicines across Europe and in the United States brings the promise of new sources of value. The prospect of more affordable options that are safe and effective opens up opportunities for health systems to expand access to biologics for more patients, free up resources for investment in new areas, and bring relief to pressured healthcare budgets.
The purpose of the report is to describe the potential role for biosimilars and their contribution to healthcare systems; the risks for stakeholders to realize that full potential value; and the requirements for competitive functioning markets in order to capture the full value.
The study is based on independent research and analysis undertaken by the IMS Consulting Group that was funded by Novartis. You can reach the white paper on Medicines for Europe website.